Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Mount Sinai researchers reprogram blood cells into iPSCs to study genetic origins of MDS

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

Theravectys gets authorization to produce lentiviral vectors for clinical use and CAR-T cell-based immunotherapy

TSRI scientists identify enzyme that maintains healthy periods of inactivity in HSCs to prevent anemia

TSRI scientists identify enzyme that maintains healthy periods of inactivity in HSCs to prevent anemia

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer

Laboratory criteria for CML deep molecular response reviewed

Laboratory criteria for CML deep molecular response reviewed

ItpkB enzyme regulates stem cells function to prevent cancer, anemia

ItpkB enzyme regulates stem cells function to prevent cancer, anemia

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

MRD-directed therapy helps boost survival of young leukemia patients

MRD-directed therapy helps boost survival of young leukemia patients

Shp2 enzyme blocks protection program, boosts tumor growth

Shp2 enzyme blocks protection program, boosts tumor growth

Scientists discover how ALL cells mutate to survive chemotherapy

Scientists discover how ALL cells mutate to survive chemotherapy

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

NCCN panelists discuss on evidence-based decision-making at bedside

NCCN panelists discuss on evidence-based decision-making at bedside

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Two American scientists receive Paul Ehrlich and Ludwig Darmstaedter Prize

Two American scientists receive Paul Ehrlich and Ludwig Darmstaedter Prize

Kalorama Information: Budding market for digital PCR reached 175 million in 2014

Kalorama Information: Budding market for digital PCR reached 175 million in 2014

New immunotoxin found to be safe, effective in patients with B-cell malignancies

New immunotoxin found to be safe, effective in patients with B-cell malignancies

Study: New gene therapy safe, effective for patients with hemophilia B

Study: New gene therapy safe, effective for patients with hemophilia B

Finding could lead to more effective, less invasive treatment for 'bubble boy' disease

Finding could lead to more effective, less invasive treatment for 'bubble boy' disease

Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

Penn researcher named a recipient of 2015 Paul Ehrlich and Ludwig Darmstaedter Prize

Melbourne researchers develop new genome editing technology to kill blood cancer cells

Melbourne researchers develop new genome editing technology to kill blood cancer cells

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.